Onyx Bridge Wealth Group LLC Sells 62 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Onyx Bridge Wealth Group LLC trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 434 shares of the medical research company’s stock after selling 62 shares during the period. Onyx Bridge Wealth Group LLC’s holdings in Thermo Fisher Scientific were worth $230,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Coppell Advisory Solutions LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $33,000. Live Oak Investment Partners purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $36,000. Tyler Stone Wealth Management purchased a new position in Thermo Fisher Scientific during the 2nd quarter valued at $37,000. Raleigh Capital Management Inc. increased its stake in Thermo Fisher Scientific by 49.1% in the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after purchasing an additional 27 shares during the period. Finally, Cedar Mountain Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 107.0% during the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 46 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded up $3.26 during midday trading on Friday, reaching $544.78. The company had a trading volume of 1,738,509 shares, compared to its average volume of 1,199,852. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The business’s 50-day simple moving average is $571.27 and its 200 day simple moving average is $527.45. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The stock has a market cap of $207.95 billion, a P/E ratio of 35.26, a P/E/G ratio of 2.28 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. The business had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company’s revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the company earned $5.40 earnings per share. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a $0.39 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,547 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $550.62, for a total value of $3,054,289.14. Following the completion of the transaction, the chief executive officer now owns 43,608 shares in the company, valued at $24,011,436.96. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 over the last three months. Company insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TMO. TheStreet upgraded shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Raymond James lifted their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. The Goldman Sachs Group increased their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Finally, Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $604.69.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.